Key points are not available for this paper at this time.
In the context of paucity of cost-effectiveness studies, our findings provide additional evidence for clinicians and payers regarding the value of a new treatment option that supports a tailored approach for the management of patients with RCTs.
Rognoni et al. (Thu,) studied this question.